Skip to main content

Table 1 Baseline characteristics of the study patients

From: Visual and anatomic outcomes of sustained single agent anti-VEGF treatment versus double anti-VEGF switching in the treatment of persistent diabetic macular edema

 Group 1Group 2p-value
Subgroup 1ASubgroup 1B
Age, mean (SD)65.5 ± (10.4)63.6 ± (7.1)72.5 ± (8.1)0.005**
Sex
 Female13 (54.2%)6 (33.3%)5 (35.7%)0.267
 Male11 (45.8%)12 (66.7%)9 (64.3%)
Type of DM
 Type 15 (20.9%)4 (22.2%)2 (14.3%)0.82
 Type 219 (79.1%)14 (77.8%)12 (85.7%)
Last known HBA1C, mean (SD)7.2 ± (0.8)7.5 ± (1.5)7.5 ± (1.2)0.91
Insulin use (%)17 (70.8%)12 (66.7%)8 (57.1%)0.89
Anti-VEGF treatment Naïve eyes (%)14 (58.3%)9 (50%)9 (64.2%)0.71
Prior focal laser treatment (%)10 (41.6%)6 (33.3%)7 (50%)0.64
Prior PRP treatment (%)5 (20.8%)2 (11.1%)0 (0%)0.17
Baseline logMAR VA, mean (SD)0.58 ± (0.29)0.65 ± (0.34)0.55 ± (0.24)0.87
Baseline CRT measurement (µm) (SD)445.92 ± (126.4)537.72 ± (131.7)410.87 ± (86.4)0.011*
  1. PRP panretinal photocoagulation, CRT central retinal subfield thickness
  2. *Group 1B patients had significantly thicker baseline CRT than other two groups. All other baseline demogrpgic data were not different between all groups
  3. **Group 2 patients had significantly older age than other groups